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Abstract:
It has been repeatedly described that increased serum ferritin concentration or hyperferritinemia is as-
sociated with COVID-19, especially with more severe forms of this disease.
Ferritin is a molecule whose concentration is determined as a marker of reflecting the body’s iron 
supply and less significantly as a marker of inflammation of infectious and non-infectious origin. The 
expression of this vital molecule for iron metabolism is therefore regulated, primarily by an iron-
dependent mechanism. However, in addition to this regulation, there appears to be feedback between 
ferritin and cytokines in the control of pro-inflammatory and anti-inflammatory mediators.
This review paper includes basic data on ferritin and the potential causes and consequences of hyper-
ferritinemia with implications for COVID-19.
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Sažetak
Hiperferitinemija i COVID-19 ?
Poznato je da je povećana koncentracija feritina u serumu ili hiperferitinemija povezana s COVID-19, 
posebno u težim oblicima ove bolesti.
Feritin je molekula čija se koncentracija određuje kao biljeg koji odražava opskrbu organizma sa 
željezom, te manje značajno kao biljeg upale infektivnog i neinfektivnog podrijetla. Ekspresija ove 
molekule neophodne za metabolizam željeza stoga je regulirana, prvenstveno mehanizmom koji ovisi 
o željezu. Međutim, pored ove regulacije, čini se da postoje i povratne informacije između feritina i 
citokina u kontroli proupalnih i protuupalnih medijatora.
Ovaj pregledni članak uključuje osnovne podatke o feritinu i potencijalnim uzrocima i posljedicama 
hiperferitinemije s implikacijama na COVID-19.
Ključne riječi: hiperferitinemija; COVID-19; upala; metabolizam željeza; feritin
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Introduction
A new coronavirus identified in December 2019 in Wuhan 
caused a pandemic known as coronavirus disease-2019 (COV-
ID-19), which is still ongoing. The vast efforts of the world 
scientific community have focused on studying both the new 
corona virus, i.e. severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) and the pathologies of the disease associated 
with this infection. The virus infects the respiratory organs, in 
severe cases the lung cells via the currently best-known recep-
tor angiotensin-converting enzyme 2 (ACE2), although some 
other possibilities for the virus to enter the cell are mentioned 1. 
Disease expression is associated with various risk factors eg. viral 
load, age, presence of comorbidities, innate and adaptive im-
mune capabilities of the host, etc. 2.
Common symptoms of the disease are different and include fe-
ver, dry cough, dyspnea, fatigue and myalgia, and less commonly 
headache, nausea, vomiting, rhinorrhea, loss of sense of smell 
and taste, depending on the stage of infection, age, comorbidities 
present, whereby not all must be involved at the same time 3. The 
clinical picture of the disease is dominated by significant inflam-
mation, respiratory problems, hypercoagulopathy, so the most 
common result of severe forms of the disease is the development 
of atypical form of acute distress respiratory syndrome (ARDS) 
with preserved lung gas volume 4, with significant cytokine 
release, progressive hypoxia, impaired coagulation, and in severe 
cases multiorgan failure 5.
COVID-19 is mostly expressed in asymptomatic or mild form 
(about 80% of cases) but also in more severe forms, which cause 
significant mortality and morbidity 6. It is still not entirely clear 
why a smaller proportion of patients develop a very severe form 
and for now an excessive adaptive immune response and virus-
induced pulmonary pathology are assumed 7. Timely identifi-
cation of individual disease phenotypes, reliable and specific 
indicators is therefore crucial for disease monitoring and for 
initiating targeted antiviral, anti-inflammatory, anticoagulant or 
even antifibrotic therapeutic approaches.
Primary respiratory problems, as well as other features of the 
disease, can, logically, based on already existing knowledge of 
respiratory pathophysiology, biochemistry and iron metabolism, 
be associated with potential disorders of iron homeostasis 8,9. As 
a consequence of dysregulation of iron homeostasis, a decrease 
in the amount of functional hemoglobin with accompany-
ing hypoxia, hypopheremia and thus hyperferritinemia can be 
mentioned 10. Iron is crucial for the host as it participates in 
a number of physiological processes, nonenzymatyc and en-
zymatic reactions. The amount of iron is strictly regulated, as 
the potential presence of free iron can result in the formation 
of free radicals through Fenton and Haber-Weiss reactions, as 
well as damage of cells and organs. On the other hand, viruses 
also need iron because they need a host metabolic apparatus for 
their replication 11. It has been described that some viruses can 
also alter the expression of proteins involved in iron homeostasis 
(e.g., hepcidin, hereditary hemochromatosis protein, etc.) 12. The 
significant role of changes in iron homeostasis in COVID-19 is 
supported by an increasing number of papers that include addi-
tional therapeutic approaches to these changes (eg. synthetic and 
naturaliron chelators, cellular iron depleting agents by regulating 
the expression of genes involved in iron metabolism, ferroptosis 
inhibitors, etc.) 13,14.
Among other things, certain phases of COVID-19 development 
are characterized by significant changes in laboratory parameters. 
For now, laboratory tests can be singled out, some of which are 
important for distinguishing mild to severe forms of the disease, 
i.e. the assessment of the prognosis of the disease. These are, for 
example, changes in some hematological parameters (lympho-
penia, neutrophilia, thrombocytopenia); coagulation parameters 
(D-dimers, prothrombin time (PT), activated partial throm-
boplastin time (APTT); indicators of systemic inflammation 
(ferritin, C-reactive protein (CRP), procalcitonin, neutrophil 
to lymphocyte ratio (NLR), cytokines); lactate dehydrogenase 
(LDH); bilirubin, etc.15.
The one of the most common and significant laboratory findings 
in patients with COVID-19 is hyperferritinemia, i.e. increased 
ferritin concentration in serum, one of the most important pro-
teins for iron homeostasis. The purpose of this review is to collect 
literature data relating to the possible causes and consequences 
of hyperferritinemia in inflammation with currently possible im-
plications for hypereferritinemia in COVID-19 patients. To this 
goal, databases (PubMed, WHO COVID-19 database, BioArx 
and MedArxiv preprint servers, Google Scholar, Embase, Web 
of Science, ScienceDirect) were reviewed. The search strategy 
was to use different search terms alone and in any combina-
tion, such as “COVID-19”, “SARS-CoV-2”, “iron”, „hepcidin“, 
„hemoglobin“, „ferritin“, hyperferritinemia“„virus infection“, 
“inflammation”, “immunity”, “cytokine”, “IL-6”, „tumor ne-
crosis factor-α, (“TNF-α”, “IL-1β.)” Only English articles with 
available data were included.
Basic characteristics of ferritin
Ferritin, primarily a cellular, non-glycosylated protein (Mr 450 
kDa), of all but especially cells of the reticuloendothelial system 
(RES; or synonym: monocyte-macrophage system - mononu-
clear-phagocyte system - MPS) and liver, is known as a molecule 
for storing iron ions, with a maximum capacity of 4500 Fe3+ per 
molecule of ferritin 16. In cells it can be localized in the cyto-
plasm, nucleus and mitochondria. Given the storage property 
of free, potentially toxic iron, this molecule is also considered a 
preventive antioxidant 17. Depending on the body’s continuous 
needs for iron, it serves as a dynamic “buffer” of iron, in main-
taining the steady-state availability of iron. According to this role 
in iron metabolism, cellular ferritin values are regulated at the 
translational level by the iron regulatory proteins/iron respon-
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sive elements (IRP/IRE) regulatory system, which is dependent 
on the amount of iron in the body 18. However, regulation by 
cytokines at the translational and transcriptional levels, especially 
in macrophages, has also been described, which could explain the 
increase in ferritin values  in inflammatory conditions 9,19,20.
Human, cellular ferritin consists of 24 light (L) chain subunits 
responsible for the stability of the molecule and storage of iron 
in the apoferritin shell, and heavy chains (H) responsible for the 
ferroxidase activity of ferritin. The result of this activity is the 
oxidation of Fe2+ to Fe3+ and thus the prevention of the potential 
formation of toxic hydroxyl radicals.
The L and H chains of ferritin are interchangeable and have 
different proportions in the ferritins of different tissues, which 
is presumably reflected in the function of this molecule 21,22. 
Thus, in the ferritin of liver tissue and spleen, the L-subunit 
predominates (basic isoferritins classified according to pI), while 
in the ferritin of the brain, kidneys and heart, the H-subunit 
predominates (acidic isoferritin classified according to pI) 17. The 
existence of ferritin in erythrocytes has also been proven, and it is 
also found in the systemic circulation, i.e. serum or plasma 23,24,25. 
The entry of Fe2+ into the ferritin molecule is enabled by the 
existence of an electrostatic gradient that attracts metal cations, 
the corresponding channels and with the help of chaperone Poly-
r(C)-Binding Protein-1 (PCBP1) 26. This is usually followed by 
its oxidation to the Fe3+ storage form via the ferroxidase activ-
ity of the H-chain of ferritin and its placement in the cavity of 
the molecule. There are different ways of mobilizing iron from 
cellular ferritin depending on the condition, and among others, 
a significant place in vivo is attributed to the decomposition of 
ferritin, the process of ferritinophagy (a subtype of autophagy). 
Serum ferritin contains less iron per molecule 27, is largely com-
posed of L-subunits in contrast to cellular ferritin. In contrast to 
the clinical potential of serum ferritin, the function or possible 
effects of serum ferritin are largely unknown at present. This 
form of ferritin is often posttranslational glycosylated (60-
80%)28, since the L-subunit contains a site for N-glycosylation 29 
and is thought to be of hepatic origin 17,29. Carbohydrate residues 
are acquired during the process of secretion from tissues into the 
systemic circulation, and the process is mediated by RES cells 
and hepatocytes 29. The degree of glycosylation can also affect 
the rate of removal of ferritin from plasma, so, as described, the 
half-life of glycosylated ferritin is significantly longer (50 hours) 
compared to non-glycosylated (5 hours) 30. Furthermore, the pro-
portions of glycosylated and non-glycosylated ferritin in serum 
appear to change during some diseases so that the proportion of 
glycosylated ferritin decreases to a level of 20% 31. In this sense, 
the saturation of known glycosylation mechanisms 32 but also cell 
damage and lysis, which is shown on liver cells 33, is considered 
as the cause of the decrease. Therefore, it is hypothesized that the 
degree of glycosylation of serum ferritin could help to differenti-
ate the underlying pathology of various diseases, more specifically 
the differential diagnosis of hyperferritinemia 34,35. These assump-
tions would be desirable to confirm and examine multiple times 
in patients with COVID-19. 
The origin of serum ferritin is still debated and is mentioned on 
the one hand by simple release from damaged cells and on the 
other by active secretion from cells via non-classical vesicular 
pathways and multivesicular body- exosome pathway 21,36,37. As 
the concentrations of ferritin in the cell are about 1000 times 
higher than those in the serum, Kell et al. present arguments 
to support the view that the occurrence of serum ferritin is 
the result of cellular stress and cell lysis („hyperferritinemia of 
cytolysis“) 21,38. In addition, they state that serum ferritin values 
correlate with markers of a) liver cell damage, b) markers of 
hydroxyl radical formation and oxidative stress, c) erythrocyte 
microparticles values and d) with the presence and/or severity of 
a number of diseases (e.g., ARDS, amyotrophic lateral sclerosis, 
atherosclerosis, cancer, cirrhosis of the liver, coronary artery 
disease, diabetes mellitus type 2, etc.). 
Active ferritin secretion is supported by some studies in mice, 
primary macrophage cultures, as well as on splenectomy in ani-
mals that resulted in a decrease in serum ferritin, also as evidence 
of macrophage contribution to serum ferritin values 36,39. 
Furthermore, the release of iron-loaded ferritin into the systemic 
circulation is mentioned, as a consequence of the inhibition of 
ferroportin (the only known exporter of iron from cells), due 
to the increased expression of hepcidin in conditions of severe 
inflammation 40. The mode of such release is unclear but putative 
mechanisms include, for example, exocytosis, secretion by secre-
tory lysosomes, and transcytosis 19,29,36. The biological significance 
of both the secretion and the utilization of the ferritin molecule 
in the systemic circulation is currently unknown. It is assumed 
that ferritin acts as an iron donor, i.e. it is introduced into e.g. 
erythroid precursors for hemoglobin synthesis 41.
Determination of serum ferritin concentration is used primarily 
to assess the body’s iron supply. Serum ferritin is also known as 
a marker of inflammation, although its role in the inflamma-
tory process is not yet clear 21. This reduces the diagnostic value 
of determining ferritin as an indicator of body iron status and a 
more accurate marker is considered to be the determination of 
the soluble transferrin receptor (sTfR): log ratio of ferritin (“sTfR 
index”) 42.
Hypereferritinemia with implications for CO-
VID-19
In addition to inflammation often called “cytokine storm”, a 
striking laboratory feature in COVID-19 is the increased serum 
ferritin concentration. Retrospective studies from several centers 
in Wuhan found that, for example, ferritin concentrations at ad-
mission were between 1.5 and 5.3 times higher in patients with 
more severe, compared to milder forms of the disease and 3-4 
times higher in non-survivors compared to surviving patients 43.
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Kappert K. et al. have tried in a review paper to find data and 
compare ferritin values in patients with COVID-19, with values  
in several other infectious diseases. For SARS-CoV, Middle East 
respiratory syndrome (MERS) and H1N1, such data were not 
even found; for influenza A, one paper described, for example, 
mean ferritin values of about 600 µg/L for patients with a poor 
outcome, compared to others with a value of about 217 µg/L. 
There are a number of studies involving ferritin values  in COV-
ID-19 patients that could be summarized as follows: in mild and 
moderate forms of the disease (as well as in surviving patients 
and patients without ARDS), serum ferritin values  were gener-
ally < 1000 µg/L, while in severe, extremely severe (non-survivors 
and non-survivors with ARDS) were > 1000 µg/L. The final con-
clusion was that there was a correlation of serum ferritin values  
with disease severity and poor final outcome for the patient 44. 
The organism, i.e. the cells, therefore react to the stress-inflam-
matory state and produce large amounts of ferritin, and whether 
ferritin is only a sign of disease progression or has a modulating 
role in the pathogenesis of the disease is still debated43,45.
Increased serum ferritin levels in the inflammatory state sup-
port the immune system, limiting the availability of iron to 
pathogens46,47. The final result of such changes, as described, is a 
decrease in the concentration of iron in the systemic circulation, 
and as a reflection of the increase in ferritin in cells, an increase 
in serum ferritin, which was also recorded in COVID-19 48,49. 
Such changes are usually a feature of changes in iron metabolism 
in the inflammatory state. Such laboratory findings are common 
in inflammation, reflecting increased concentrations of hepcidin, 
the major iron regulator, and indirectly ferritin. Additionally, 
in the literature, based on the similarity of part of the spike 
glycoprotein structure of SARS-CoV-2 virus and hepcidin, it is 
hypothesized that this protein could have a hepcidin-like effect 10. 
This would mean that this viral protein may further increase cel-
lular and serum concentrations ferritin regardless of the inflam-
matory effect, which should certainly be supported by further 
experimental research.
Reports of decreased ferritin and IL-6 levels in accordance with 
the recovery of patients with COVID-19 50 on the one hand con-
firmed the association of hyperferritinemia with inflammation 
and indicated a potential role as a parameter indicating disease 
severity and cytokine storm extent. On the other hand, they also 
stimulated considerations about the possible role of ferritin as a 
participant in the inflammatory process itself 51, considering both 
the immunosuppressive 52,53,54 and pro-inflammatory properties 
of ferritin 55.
There are reports of complex feedback mechanisms between 
ferritin and cytokines in the control of pro-inflammatory and 
anti-inflammatory mediators. The process of ferritin synthesis is 
stimulated by cytokines at both the transcriptional and trans-
lational levels in a variety of cells, including macrophages 51,56. 
Cytokines, including IL-6, IL-1β, and TNF-α can stimulate the 
expression and subsequent secretion of ferritin from, for example 
macrophages. The macrophages that make up most of the im-
mune cells in the lung parenchyma are the main “pool” of iron as 
they phagocytose obsolete erythrocytes 52,57. It has been described 
that the expression of relative ratios of ferritin subunits is affected 
by inflammation, i.e. that cytokines and paracrine signaling mol-
ecules such as nitrogen monoxide, increase the relative content of 
the H-subunit and directly affect the IRP/IRE control system58. 
In addition to modulating expression via mentioned system, 
there is also modulation in an IRP/IRE-independent manner, as 
shown in vitro on fibroblasts treated with TNF-α and IL-1α with 
an increase in the H-subunit of ferritin 59. According to current 
knowledge, the expression of the H-subunit of ferritin is most 
often increased by inflammatory stimuli.
It has been shown that ferritin as a signaling molecule can 
induce the expression of pro-(e.g. IL-1β) and anti-inflammatory 
cytokines (e.g. IL-10) 43,54. The immunomodulatory properties 
of ferritin are attributed to the increased expression of the H-
subunit of ferritin 9,17. According to Shoenfeld et al., the H-chain 
of ferritin could be important in macrophage activation in terms 
of increased secretion of inflammatory cytokines and in COV-
ID-19 60 whose clinical picture resembles macrophage activation 
syndrome. Based on some experimental research on activated 
rat hepatic stellate cells, the possibility of a direct causal role of 
ferritin in the inflammatory process, i.e. the action of ferritin as a 
local cytokine 61, cannot be ruled out, which should certainly be 
examined in the case of COVID-19.
Based on in vitro studies, it has been shown that T and B 
lymphocytes and other cell types bind directly to the H-subunit 
of ferritin during inflammation, by a hitherto unknown mecha-
nism52,62, although various potential receptors are also listed. 
The result is an immunosuppressive effect, more specifically a 
reduction in T-cell proliferation, B-cell maturation, and immu-
noglobulin production 61,62,63.
Significant hyperferritinemia accompanied by inflammation with 
a cytokine storm, called hyperferritinemic syndrome” (includes: 
Macrophage activation syndrome (MAS), Adult-onset Still’s dis-
ease (AOSD), Catastrophic antiphospholipid syndrome (CAPS), 
and Septic shock) is also characterized by COVID 19, so this 
disease currently considered as the fifth member within the 
definition of hyperferritinemic syndrome 64. Common features of 
this syndrome and COVID-19 in addition to hyperferritinemia 
are: lymphopenia, decreased number and activity of natural killer 
(NK) cells, abnormal liver function tests and coagulopathy 54.
Some authors associate certain morphological changes of 
erythrocytes such as deformability and shorter half-life with an 
increase in free, potentially toxic iron values derived from fer-
ritin released from damaged cells 21,65. It is also mentioned in the 
literature that the change of fibrin from the usual mesh layer to 
a turbid mass which can result in the formation of a rigid clot 
resistant to fibrinolysis 21,66 and contribute to vascular problems 
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in various diseases. Pharmacological (eg. deferoxamine) or nu-
tritional (polyphenolic antioxidants) iron chelators are therefore 
recommended as adjunctive therapy to counteract the effects of 
released iron 67.
Hyperferritinemia, with consequent ferritinophagia, is also 
crucial for the induction of a specific, relatively new form of 
regulated cell death of ferroptosis 68. Ferroptosis is an inherently 
more immunogenic form of death than for example, apopto-
sis, because the affected cells release inflammatory cytokines 
and damage-associated molecular patterns (DAMPs), which 
contribute to the proinflammatory state 69,70. In addition to 
DAMPs, some ferroptotic cells can release high mobility group-1 
(HMGB1) in a manner associated with autophagy, a molecule 
that is also involved in the pathogenesis of inflammation 71. The 
association of ferritinophagy and ferroptosis has been described 
and ferritinophagy is thought to be one of the key events in 
ferroptosis 72,73. The process of ferritinophagy involves the cargo 
receptor nuclear receptor coactivator-4 (NCOA4) which binds 
to ferritin, more precisely to the H-subunit of ferritin, transmits 
it from the cytosol to the lysosomes 74. The result is the release 
of free iron and the consequent formation of lysosomal reactive 
oxygen species 75. It can therefore be concluded that changes in 
ferritin expression affect ferroptosis by altering the intracellular 
pool of free and redox active iron 76.
Ferroptosis is a type of iron-dependent cell death that also causes 
an irreversible change in the morphology of mitochondria 77, 
organelles necessary to provide the energy needed for cellular func-
tions in accordance with bodily needs. Mitochondrial homeostasis 
disorders are therefore involved in the pathogenesis of various 
diseases 78. Hyperferritinemia can affect mitochondrial homeostasis 
and thereby redirect mitochondria from the aerobic to the anaero-
bic state. Such changes would be consistent with the increased 
LDH values observed in patients with COVID-19 5,79. According 
to Hirschhorn T. et al. hyperferritinemia leads to severe oxidative 
stress, lipoperoxidation, and mitochondrial-level ferroptosis, and 
increases mitophagy with accelerated cell death 80. The question 
can be asked whether, for example, hyperferritinemia and insuf-
ficient mitochondrial capacity of iron metabolism in COVID-19 
cause ferroptosis of the bronchial epithelium, but also other cells?
Opinions differ on the significance of hyperferritinemia. From 
being an “innocent passer-by”, a biological marker of uncon-
trolled inflammation, to ferritin having a protective role, to 
being a key mediator of immune dysregulation in conditions 
of extreme hyperferritinemia, through immunosuppressive and 
pro-inflammatory effects 9,81. Hyperferritinemia is also potentially 
associated with an increase in free redox active iron, which can 
further cause a number of direct and indirect organ disorders 
during COVID-19. It is possible that in COVID-19 there may 
be a vicious cycle of inflammation, associated with dysfunction of 
iron homeostasis and increased serum ferritin levels, which may 
lead to tissue damage (Figure 1.).
Concluding remarks
The knowledge about the SARS-CoV-2 and its associated disease 
is continuously successfully collected but still keeps the world 
in suspense. Given the relatively high proportion of hospitalized 
patients but also deaths, it is necessary to define and validate new 
existing clinically relevant and reliable diagnostic and prognos-
 
Figure 1. Potential role of hyperferritinemia during inflammation in COVID-19.
(1) Infection with SARS-CoV-2; (2) Activation of hepcidin expression by IL-6; (3a) The result of the increase in hepcidin is the 
enhanced storage of iron within ferritin in macrophages; (3b) The result of the increase in hepcidins the decreased serum iron as well 
as increased ferritin values, i.e. hyperferritinemia; (4) Enhanced synthesis and secretion of ferritin from macrophages due to cytokine 
action; (5) Immunomodulatory effect of hyperferritinemia; (6) Further stimulating inflammation by the immunoactivation effects of 
ferritin; (7a) and (7b). Further consequences of macrophage activation. (SARS-Cov-2) severe acute respiratory syndrome coronavirus-2; 
(IL) interleukine; (TNFα) tumor necrosis factor α; (↑) increased value; (↓) decreased value.
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tic clinical and laboratory markers of COVID-19. This would 
increase the understanding of the pathogenesis of the disease and 
facilitate a proper therapeutic approach.
Numerous reports to date have shown increased serum fer-
ritin to have clinical and discriminatory potential to define the 
severity of COVID-19. Due to the similarity of several labora-
tory features, this disease is increasingly mentioned as a possible 
fifth member of the so-called “hyperferritinemiy syndrome”. 
However, ferritin is not a specific laboratory marker, as increased 
concentrations have been reported in other inflammatory condi-
tions of infectious and non-infectious origin.
As hyperferritinemia appears to identify COVID-19 patients 
at high risk of mortality, and its reduction indicates improved 
survival, there is a need for further investigation the structure and 
role of ferritin in inflammatory conditions on the one hand as a 
biomarker, but on the other hand as a mediator of COVID-19.
In order to increase the diagnostic specificity of increased serum 
ferritin values in predicting disease progression and association 
with the inflammatory process, further targeted and well-planned 
multicenter studies on a larger number of samples need to be 
done. Accordingly, it is necessary to determine ferritin values in 
better defined groups of patients, including asymptomatic infected 
persons, persons in the very early stages of the disease, non-
hospitalized patients with mild COVID-19, subjects of different 
age groups. It should be also monitored ferritin values during the 
disease to establish the value of this analyte in terms of monitor-
ing current and future therapeutic approaches as well as the effects 
of developing vaccines; setting limit values  on the basis of which 
patients could be classified into groups in terms of an appropriate 
therapeutic approach; defining critical ferritin values. In order to 
assess the contribution of possible hypopheremia to concomitant 
hyperferritinaemia, in a condition such as severe inflammation 
and its association with hypoxia associated with poor outcomes in 
COVID-19, determine the values  of other coexisting participants 
in iron metabolism (eg. iron concentration, hemoglobin, hepcidin 
transferin saturation). In other words, it is important to establish 
the reliability of determining serum ferritin concentration in 
reflecting the severity of COVID-19 and its monitoring.
The mechanisms by which hyperferritinemia contributes to the 
pathogenesis of COVID-19 are currently unclear. We hope, 
therefore, that in this sense, this brief review will encourage further 
research, inter alia in the direction of: defining the immunomodu-
latory properties of ferritin by comparatively determining the val-
ues  of pro-inflammatory and anti-inflammatory cytokines; based 
on the definition of the ratio of L and H-chains to determine the 
origin of serum ferritin; determination of iron in serum ferritin; 
assess whether and to what extent macrophage activation contrib-
utes to hyperferritinemia in COVID-19 by determining the degree 
of serum glycosylation of ferritin, value of sCD163 and circulating 
microparticles (cMPs), also indicators the monocyte-macrophage 
activity; examining whether hyperferritinemia may be a target for 
therapeutic intervention; and, for example, testing the sensitivity 
of iron-enriched tissue macrophages to SARS-CoV-2 and its abil-
ity to generate de novo infectious viral particles. 
As in most systematic reviews, this one has some limitations 
that of course require further discussion and confirmation. 
COVID-19 is a new disease and although the focus of scientific 
research has been limited due to lack of reliable information - 
some published papers are theoretical in nature, some papers 
provide only partial information, some papers have not passed 
peer review, in some cases conclusions are based on limited 
amounts of data and should be confirmed by additional research. 
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